ClinicalTrials.gg
CompletedNCT00511979Updated Jun 26, 2012

Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin

A Phase 1 interventional study of Technosphere Insulin and Technosphere insulin in Healthy, sponsored by Mannkind Corporation. Completed. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-26.

Sponsored by Mannkind Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

A prospective, single center, open randomized, six way crossover study comparing the dose response effect of four different doses of Technosphere Insulin after pulmonary function delivery in comparison to s.c. injection of two different doses of regular human insulin.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Patients
03

In context

Lead sponsor

Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be in good health, as judge by brief history and physical examination.
  • Sex: both, male and female.
  • Age: 18-40 years.
  • : 18-27 kg/m2.
  • Capability to reach peak inspiratory flow of >41/sec measured by a computer assisted spirometry.
  • equal to or greater than 80% of predicted normal.

Exclusion criteria

Exclusion Criteria:

  • Diabetes Mellitus type 1 or type 2.
  • Human insulin antibodies.
  • Anamnestic history of to the study medication or to drugs with similar chemical structures.
  • Having a history of severe or multiple allergies.
  • Treatment with any other drug in the last three months before study entry.
  • Progressive fatal disease.
  • History of significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and /or hematological disease.
  • Having ongoing respiratory tract infection.
  • Smoker defined as subjects with evidence or history of tobacco or nicotine use in the last year prior to entry in the study.
  • Blood donation within the last 30 days.
  • A woman who is lactating.
  • Pregnant women or women intending to become pregnant during the study.
  • A sexually active woman of childbearing age not actively practicing or using medically accepted device or therapy.
  • A lack of compliance or other reasons, which prevent to the opinion of the investigator the participation of the subject in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Technosphere insulin inhalation system, 25 units

    Drug: Technosphere Insulin

  • Experimental
    Technosphere insulin inhalation system, 50 units

    Drug: Technosphere insulin

  • Experimental
    Technosphere insulin inhalation system, 100 units

    Drug: Technosphere insulin

  • Active comparator
    Subcutaneous regular human insulin

    Drug: Regular human insulin

06

What researchers measure

Primary outcomes

  1. Dose-corrected area-under-the serum insulin concentration vs. time curve for inhaled TI and subcutaneous RHI at timepoints -120, -90, -60, 0, 1, 3, 7, 12, 20, 30, 45, 60 and 90 minutes, and 2, 3, 4, 5 and 6 hours relative to treatment

    Time frame: crossover every 3-28 days for up to 20 weeks

  2. Area under the glucose infusion rate for inhaled TI and subcutaneous RHI at timepoints -120, -90, -60, 0, 1, 3, 7, 12, 20, 30, 45, 60 and 90 minutes, and 2, 3, 4, 5 and 6 hours relative to treatment

    Time frame: crossover every 3-28 days for up to 20 weeks

Secondary outcomes

  1. Safety variables included adverse events (AEs), clinical laboratory tests, HbA1c, pulmonary function tests, vital signs, physical examinations, and diabetes-specific signs (ie, hypoglycemia)

    Time frame: crossover every 3-28 days for up to 20 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1999, a primary completion of Feb 2000 and a completion of Jun 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2007
First posted
Aug 6, 2007
Start
Aug 1999
Primary completionActual
Feb 2000
CompletionActual
Jun 2000
Last update
Jun 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00511979
Responsible party
Sponsor
First posted
Aug 6, 2007
Start date
Aug 1999
Primary completion
Feb 2000
Completion
Jun 2000
Last update
Jun 26, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion